Jeffrey S. Weber, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the results of a phase III randomized, open-label study of nivolumab compared with investigator's choice chemotherapy for the treatment of patients with advanced melanoma after prior anti-CTLA-4 therapy.
There was a clear advantage to nivolumab in this study. On the trial, 32% of patients treated with nivolumab responded (RECIST 1.1) compared with 11% of those treated with chemotherapy.
Toxicities between the arms were very different, Weber says. Patients treated with chemotherapy experienced toxicity to the bone marrow and high levels of fatigue. In total, 9% of patients on the nivolumab arm experienced grade 3/4 toxicities compared with 31% of patients treated with chemotherapy.
<<< View more from the 2014 ESMO Congress